Cargando…
S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA
BACKGROUND: Most investigations into the pharmacology of schizophrenia have revolved around dopaminergic and glutamatergic neurotransmission; however, one neurotransmitter that has not received adequate attention is the cholinergic system. Indeed, several post-mortem, genetic and epidemiologic studi...
Autores principales: | Neves, Gilda, Grace, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887315/ http://dx.doi.org/10.1093/schbul/sby018.1019 |
Ejemplares similares
-
S37. STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
por: Sonnenschein, Susan, et al.
Publicado: (2018) -
Nicotine Administration Normalizes Behavioral and Neurophysiological Perturbations in the MAM Rodent Model of Schizophrenia
por: Weeks, Jillian J, et al.
Publicado: (2021) -
Increased elasticity of sucrose demand during hyperdopaminergic states in rats
por: Minnaard, A. Maryse, et al.
Publicado: (2022) -
T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018) -
A neuronal mechanism underlying decision-making deficits during hyperdopaminergic states
por: Verharen, Jeroen P. H., et al.
Publicado: (2018)